US5175145A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment of diabetes mellitus with amylin agonists
Assignee: Amylin Pharmaceuticals LLC
•
Filing: 1992-01-14
•
Granted: 1992-12-29
•
Expires: 2012-01-14
Abstract
Abstract Novel methods for treating diabetes mellitus and hyperglycemia are described which comprise administering to a diabetic or hypoglycemic subject an amount of an amylin agonist effective to induce amylin activity in said subject. Various amylin agonist compounds, and therapeutic methods utilizing such compounds, are also disclosed.
Inventors
- 👤 Garth J. S. Cooper
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 19:38
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/225; A61K38/28
Claims Analysis
Total Claims: 28
Claim 1
Independent Claim
28 words
A method of treating diabetes mellitus in a subject comprising administering to said subject an amount of an amylin agonist effective to induce amylin activity in said subject.
Claim 2
Independent Claim
28 words
A method of treating diabetes mellitus in a subject comprising administering to said subject an amount of an amylin agonist effective to induce amylin activity in said subject.
Claim 3
Dependent Claim
11 words
The method of claim 1 wherein said amylin agonist is amylin.
Claim 4
Dependent Claim
11 words
The method of claim 1 wherein said amylin agonist is CGRP.
Claim 5
Dependent Claim
15 words
The method of claim 1 wherein said amylin agonist is a conservative variant of amylin.
Claim 6
Dependent Claim
15 words
The method of claim 1 wherein said amylin agonist is a conservative variant of CGRP.
Claim 7
Dependent Claim
11 words
The method of claim 2 wherein said amylin is human amylin.
Claim 8
Dependent Claim
11 words
The method of claim 3 wherein said CGRP is human CGRP.
Claim 9
Independent Claim
27 words
A method of treating hypoglycemia in a subject comprising administering to said subject an amount of an amylin agonist effective to induce amylin activity in said subject.
Claim 10
Independent Claim
27 words
A method of treating hypoglycemia in a subject comprising administering to said subject an amount of an amylin agonist effective to induce amylin activity in said subject.
Claim 11
Dependent Claim
11 words
The method of claim 8 wherein said amylin agonist is amylin.
Claim 12
Dependent Claim
11 words
The method of claim 8 wherein said amylin agonist is CGRP.
Claim 13
Dependent Claim
15 words
The method of claim 8 wherein said amylin agonist is a conservative variant of amylin.
Claim 14
Dependent Claim
15 words
The method of claim 8 wherein said amylin agonist is a conservative variant of CGRP.
Claim 15
Dependent Claim
11 words
The method of claim 9 wherein said amylin is human amylin.
Claim 16
Dependent Claim
11 words
The method of claim 10 wherein said CGRP is human CGRP.
Claim 17
Dependent Claim
19 words
The method of claim 1 or 8 further comprising administering a predetermined amount of an insulin to said subject.
Claim 18
Independent Claim
18 words
A method of treating diabetes mellitus comprising administering a pharmaceutical composition comprising an amylin agonist and an insulin.
Claim 19
Independent Claim
18 words
A method of treating diabetes mellitus comprising administering a pharmaceutical composition comprising an amylin agonist and an insulin.
Claim 20
Dependent Claim
21 words
The method of claim 16 wherein the molar ratio of said insulin to said amylin agonist is from 100:1 to 0.1:1.
Claim 21
Dependent Claim
11 words
The method of claim 16 wherein said amylin agonist is amylin.
Claim 22
Dependent Claim
11 words
The method of claim 18 wherein said amylin is human amylin.
Claim 23
Dependent Claim
14 words
The method of claim 1 or 8 wherein said amylin agonist is administered parenterally.
Claim 24
Dependent Claim
11 words
The method of claim 15 wherein said insulin is administered parenterally.
Claim 25
Dependent Claim
11 words
The method of claim 16 wherein said composition is administered parenterally.
Claim 26
Dependent Claim
20 words
The method of claim 1 or 8 wherein amylin agonist is administered in a vehicle suitable for delayed release administration.
Claim 27
Dependent Claim
18 words
The method of claim 15 wherein said insulin is administered in a vehicle suitable for delayed release administration.
Claim 28
Dependent Claim
18 words
The method of claim 16 wherein said composition is administered in a vehicle suitable for delayed release administration.
References Cited (Backward Citations)
GB2141430A
Cited
US4530839A
Cited
WO1985001658A1
Cited
US4736023A
Cited
EP0156772A2
Cited
EP0188400A2
Cited
US4720483A
Cited
US4687839A
Cited
US4697002A
Cited
EP0263802A1
Cited
EP0270376A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-12-29 | 1996-06-29 | 1996-12-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-12-29 | 2000-06-29 | 2000-12-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-12-29 | 2004-06-29 | 2004-12-29 | $7700.00 | Window Closed / Lapsed |